File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600001881197

Numelvi 4.8 mg - Tablet

Authorised

- Atinvicitinib

Product identification

Medicine name:
Numelvi 4.8 mg - Tablet

Active substance:
Atinvicitinib

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Atinvicitinib
4.80 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QD11AH93

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Austria , Germany , Portugal

Package description:
Packaging:Cardboard box, Package_size:30 tablets
Packaging:Polyethylene bottle, Package_size:90 tablets
Packaging:Cardboard box, Package_size:90 tablets
Packaging:Polyethylene bottle, Package_size:30 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - new active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
24/07/2025

Manufacturing sites for batch release:
Intervet Ges.m.b.H.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
24/07/2025

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 13/03/2026
Download

ema-puar-v6480-numelvi-initial-en.pdf